EduFacts Scientific Write-ups - Polyphenols Bolster Drug Effects in Ocular Hypertension
Polyphenols Bolster Drug Effects in Ocular Hypertension Ocular Hypertension and Risk of Glaucoma Ocular hypertension is a leading risk factor for the development of primary open angle glaucoma (POAG), and is the only modifiable risk factor acknowledged at present. Its estimated that 4 to 7% of Americans over 40 years of age have ocular hypertension. The Ocular Hyper-tension Treatment Study (OHTS) clearly showed that lowering IOP is effective in delaying or preventing the onset of POAG in individuals with ocular hypertension. Recent results from a long-term study by the OHTS group indicates that those at high risk of POAG can benefit from early preventive treatment (1). Spurred by previous findings that a combination of polyphenols (anthocyanins and procyanidins) could improve IOP and blood flow in ocular hypertension, the same researchers recently compared the effects of those polyphenols alone and with latanoprost in ocular hypertensive patients with no signs of POAG (2). Study Design The ...
Ocular hypertension - Wikipedia
Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure), usually with no optic nerve damage or visual field loss. For most individuals, the normal range of introcular pressure is between 10 mmHg and 21 mmHg. Elevated intraocular pressure is an important risk factor for glaucoma. The Ocular Hypertension Treatment Study, a large, multicentered, randomized clinical trial, determined that topical ocular hypotensive medication delays or prevents the onset of Primary Open-Angle Glaucoma. Accordingly, most individuals with consistently elevated intraocular pressures of greater than 21mmHg, particularly if they have other risk factors, are treated in an effort to prevent vision loss from glaucoma. The pressure within the eye is maintained by the balance between the fluid that enters the eye through the ciliary body and the fluid that exits the eye through the trabecular meshwork. Ocular hypertension is treated with either medications or laser. Medications ...
OCULAR HYPERTENSION - iBLOGalot
What Is Ocular Hypertension? Eye pressure is expressed in millimeters of mercury (mm Hg), the same unit of measurement used in weather barometers. While normal eye pressure has historically been considered a measurement of less than 21 mm Hg, this normal normal upper limit may vary in different populations. Ocular hypertension is not the same…
Prediction of Development of Glaucoma in Ocular Hypertensive Patients | SpringerLink
This multivariate analysis study was designed to identify parameters to predict which ocular hypertensive (OHT) patients will remain OHT during follow-up and which will develop glaucoma. Material...
Global assessment of retinal ganglion cell synapses in a mouse model of ocular hypertension | IOVS | ARVO Journals
Purpose: Glaucoma is a neurodegenerative disorder characterized by retinal ganglion cell (RGC) loss with optic nerve cupping and visual field defects. Disease mechanisms are not well understood, but evidence suggests that the pathological degeneration of a stressed RGC is compartmentalized at the subcellular level, with changes in the synaptic, dendritic, and axonal compartments. The purpose of this study is to determine the effects of laser-induced ocular hypertension (LIOH) on excitatory synapse number in the inner plexiform layer of the retina.. Methods: Intraocular pressure (IOP) was elevated unilaterally using laser photocoagulation of the limbal and episcleral vessels of adult CD-1 mouse eyes. IOP was measured by rebound tonometry. Retinas were dissected and prepared for whole-mount retina immunohistochemistry using PSD95 to label excitatory postsynaptic sites of RGCs in the inner plexiform layer. Brn3a was used to label RGCs in the ganglion cell layer.. Results: After laser-induced ocular ...
Americans lack knowledge of ocular hypertension | EurekAlert! Science News
A national survey of 2,037 Americans sponsored by Santen Incorporated found that only 27% have heard of ocular hypertension, a generally symptomless condition that can be a precursor to glaucoma. Only 7% of those who were aware of ocular hypertension know that it has no symptoms. Additionally, only 29% of the group at increased risk for ocular hypertension -- those aged 40 and older - are aware of the condition or the need for regular screening.
Corticosteroid-induced ocular hypertension. II. An acquired form. | British Journal of Ophthalmology
Thirty-five patients with unilateral closed-angle glaucoma treated by peripheral iridectomy and prophylactic peripheral iridectomy in the fellow eyes were subjected to corticosteroid provocative test in both eyes. 51% of the eyes with closed-angle glaucoma and 11% of their fellow eyes had a positive corticosteroid pressure response. The closed-angle glaucoma eyes had their fellow eyes responded differently as shown by the frequency distribution graphs and also by the difference between the corticosteroid-induced change in pressure (Wilcoxon test, z=-4.80, p less than 0.0001). These results provide evidence for an acquired form of corticosteroid-induced ocular hypertension and the possible pathogenic factors for the first time. The clinical significance of an acquired form of corticosteroid-induced ocular hypertension is discussed. ...
Ocular hypertension
Ocular hypertension is defined as pressure in the eyes that is higher than normal. Learn about the possible causes of ocular hypertension by reading here.
Ocular hypertension overview --Doctors Lounge
Ocular hypertension is the presence of elevated intraocular pressure above 21 mmHg regardless of whether glaucomatous nerve damage is present or not.. The normal range of introcular pressure is between 10 mmHg and 21 mmHg. Elevated intraocular pressure above 21 mmHg predisposes to open-angle glaucoma and subsequent visual field loss, optic nerve damage and loss of vision.. ...
Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients...
PURPOSE
To compare the tolerance and peak intraocular pressure (IOP)-lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta-blockers.
DESIGN
A prospective, multicenter, double-masked, parallel-design clinical trial.
PARTICIPANTS
One hundred fifteen patients with IOP inadequately controlled on topical beta-blocker monotherapy.
METHODS
Patients were randomly assigned to receive brimonidine, 0.2%, twice a day or latanoprost, 0.005%, every day as adjunctive therapy for 3 months. After 1 month of adjunctive treatment, patients who failed to meet a target 15% reduction in IOP at peak drug effect were crossed over to the other study medication. The target sample size of 51/group gave a power of 0.80 to detect a difference of 1 mmHg in mean IOP lowering between groups.
MAIN OUTCOME MEASURES
The primary outcome variables were reduction in IOP from baseline at peak drug effect, response rate, and quality of life as
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma - Full Text View - ClinicalTrials.gov
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days ...
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma - Full Text View - ClinicalTrials.gov
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days ...
Ocular hypertension - Wikipedia
Ocular hypertension is treated with either medications or laser. Medications that lower intraocular pressure work by decreasing aqueous humor production and/or increasing aqueous humor outflow. Laser trabeculoplasty works by increasing outflow. The cannabinoids found in cannabis sativa and indica (marijuana) have been shown to reduce intraocular pressure, by up to 50% for approximately four to five hours. But due to the duration of effect, significant side-effect profile, and lack of research proving efficacy, the American Glaucoma Society issued a position statement in 2009 regarding the use of marijuana as a treatment for glaucoma.[6]. ...
Phase 2a study of AR-12286 for treatment of glaucoma and ocular hypertension - MPR
Aerie Pharmaceuticals announced positive results from a Phase 2a study of AR-12286 for the treatment of primary open angle glaucoma or ocular hypertension.
ADRENERGIC DRUGS AND INTRAOCULAR PRESSURE: SUPPRESSION OF OCULAR HYPERTENSION INDUCED BY WATER LOADING
O:13:\PanistOpenUrl\:36:{s:10:\\u0000*\u0000openUrl\;N;s:6:\\u0000*\u0000idc\;N;s:6:\\u0000*\u0000fmt\;s:7:\journal\;s:6:\\u0000*\u0000doi\;s:0:\\;s:6:\\u0000*\u0000pii\;s:0:\\;s:7:\\u0000*\u0000pmid\;s:0:\\;s:9:\\u0000*\u0000atitle\;s:102:\ADRENERGIC DRUGS AND INTRAOCULAR PRESSURE: SUPPRESSION OF OCULAR HYPERTENSION INDUCED BY WATER LOADING\;s:9:\\u0000*\u0000jtitle\;s:0:\\;s:9:\\u0000*\u0000stitle\;s:0:\\;s:7:\\u0000*\u0000date\;s:4:\1980\;s:9:\\u0000*\u0000volume\;s:0:\\;s:8:\\u0000*\u0000issue\;s:0:\\;s:8:\\u0000*\u0000spage\;s:0:\\;s:8:\\u0000*\u0000epage\;s:0:\\;s:8:\\u0000*\u0000pages\;s:0:\\;s:7:\\u0000*\u0000issn\;s:0:\\;s:8:\\u0000*\u0000eissn\;s:0:\\;s:9:\\u0000*\u0000aulast\;s:7:\ROWLAND\;s:10:\\u0000*\u0000aufirst\;s:2:\JM\;s:9:\\u0000*\u0000auinit\;N;s:10:\\u0000*\u0000auinitm\;N;s:5:\\u0000*\u0000au\;a:1:{i:0;s:9:\POTTER ...
Ocular Hypertension; Glaucoma, Suspect; Hypertension, Ocular
Ocular Hypertension; Glaucoma, Suspect; Hypertension, Ocular. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Ocular Hypertension Archives - InSight Vision Center
Ocular hypertension or Intraocular pressure (IOP) is a condition in which your eye pressure gets higher than the average level. If left untreated, IOP can lead to glaucoma and permanent loss of vision. 3 to 6 million Americans are at risk of suffering from glaucoma due to high Eye pressure. Therefore you need to be well-informed about its causes, diagnosis and treatment.. ...
Response to Topical Epinephrine: A Practical Prognostic Test in Patients With Ocular Hypertension | JAMA Ophthalmology | JAMA...
• Eighty patients with ocular hypertension (intraocular pressure >20 mm Hg) and GG-response to topical corticosteroids (over 31 mm Hg after six weeks of topi
What is Ocular Hypertension and what does it mean for me?
Ocular Hypertension
Ocular Hypertension
Ocular Hypertension
Ocular Hypertension
Uveitis-related ocular hypertension: clinical profile | Ophthalmology Xagena
On multiple logistic regression, age greater than 60 years ( p=0.025 ), peripheral anterior synechiae ( PAS ) more than 180° ( p=0.029 ), and steroid use ( p less than 0.001 ) were found to have significant association with ocular hypertension ...
Frequency doubling technology, optical coherence technology and pattern electroretinogram in ocular hypertension | BMC...
Glaucoma is the second cause of blindness worldwide [1] and an early diagnosis is important to treat it promptly in order to avoid or reduce the progression of visual field defects. At least 25 to 30% of RGC is already lost when visual field defects are detectable by SAP [21]. Elevated IOP is the most important risk factor for glaucoma onset and progression [22], but the treatment of only high-risk patients with OH should be considered [23]. So, it is important to identify those patients with elevated IOP who have early stage glaucoma in order to decide when patient need a therapy.. In our study OCT of the retinal nerve fiber layer revealed a significant reduction in thickness in the inferior quadrant of the optic disc in OH compared with healthy controls, with a sensitivity of 82% and a specificity of 74%. Several studies suggested that optic nerve and RFNL impairment can generally be identified before SAP alterations [24-26]. We could speculate that at the onset of glaucoma, only the ...
Glaucoma Diagnostics
Extensive research on ocular hypertensives (patients with high pressure but no other signs of glaucoma) has given us the data that makes it possible to determine a patients five year risk for glaucoma. The elevated eye pressure measurement, as well as other diagnostic test results, are entered into a special risk calculator. When the calculator indicates that the five year risk for glaucoma development is less than 5%, the patient can be safely watched and does not require treatment. Treatment is considered if the risk is between 5% and 15%, although many patients at this moderate risk level can also be safely watched. If the risk for glaucoma development is greater than 15%, the patient is considered to be a high risk and treatment is usually initiated to lower eye pressure. , ...
Retinotopic glial alterations on the Superior Colliculus in an experimental model of glaucoma | IOVS | ARVO Journals
At 6 weeks of ocular hypertension, a significant decrease in the anterograde transport to the SC, and an increase of Iba1, RIP and O1 levels, Iba1(+) and PDGFRα(+) cell number in the lateral portion of the SC, without changes in RGC number, were observed. At 15 weeks of treatment, Brn3a(+) cell number significantly decreased, CTB transport to the SC was completely abolished, RIP and O1 levels remained increased, and the microglial response augmented and progressed through the medial SC, accompanied by the presence of ED1-phagocytic cells. The number of TUNEL(+) cells in the SC significantly increased at 6 and 15 weeks of ocular hypertension. In contrast, Vglut2 immunoreactivity and NeuN(+) cell number remained unchanged. A pronounced astroglial response (GFAP) was evident in the whole SC at 15 (but not 6) weeks of hypertension. MBP immunoreactivity was unchanged at both time points, but there was an apparent loss in Red Oil staining at 15 weeks of ocular hypertension.. ...
NCT00402493 | Glaucoma, Ocular Hypertension Clinical Trial | Pfizer
Topical IOP-lowering therapy has the advantage of providing a drug level directly to the end organ with very little or no systemic absorption thereby reducing side effect potential. There is very little information in the ophthalmic literature regarding potential drug interactions between topical IOP-lowering medications and other medications taken orally for other medical reasons. Patients will be randomized to either latanoprost or brimonidine. Patients in both groups will be randomized to either placebo or ibuprofen for the first 14 days and then crossed over to the other treatment for 14 days ...
Induction of amyloid-β(1-42) in the retina and optic nerve head of chronic ocular hypertensive monkeys. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Glaucoma & Ocular Hypertension - Mr Anish Shah FRCOphth
What is glaucoma? The eyeball is a pressurised structure, like a football. At the back of the eye, there is a small circular opening or canal in the eye wall, from which stems a stalk-like structure called the optic nerve. This nerve carries all of the visual signals from the retina to the brain. Some…
Increased corneal thickness in patients with ocular hypertension. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Glucocorticoids, Ocular Hypertension, and Glaucoma - UNT Health Science Center
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2021 Elsevier B.V We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. ...
Ocular Hypertension | The Canadian Association of Optometrists
RESEARCH: Results of an Environmental Scan to Determine the Level of Uncorrected Refractive Error in First Nations Elementary School Children in Ontario, Résultats dune analyse du milieu visant à déterminer le niveau derreur de réfraction non corrigée ...
Share link to this page
Zangwill LM, Jain S, Dirkes K, He F, Medeiros FA, Trick GL, Brandt JD, Cioffi GA, Coleman AL, Liebmann JM, Piltz-Seymour JR, Gordon MO, Kass MA, Weinreb RN, Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment ...
Higher Antioxidant Levels Linked to Protection Against Glaucoma
A team of researchers provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Glaucoma Evaluation & Treatment<...
Durysta (bimatoprost implant)
Approved March 2020 for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension.
How does blood pressure affect glaucoma? | Reference.com
Both high blood pressure (hypertension) as well as high pressure in the eye (ocular hypertension) can cause damage to the optic nerve, which may lead to glaucoma. Hypertension can also worsen ocular...
Aerie climbs after FDA briefing concurs with efficacy claims | FierceBiotech
Aerie Pharmaceuticals has received good news going into its FDA advisory committee meeting. The FDA agreed with the efficacy conclusion Aerie reached to support its bid for approval of glaucoma and ocular hypertension hopeful Rhopressa.
The effects of acute intraocular pressure elevation on rat retinal glutamate transport<...
TY - JOUR. T1 - The effects of acute intraocular pressure elevation on rat retinal glutamate transport. AU - Holcombe, David J.. AU - Lengefeld, Nadia. AU - Gole, Glen A.. AU - Barnett, Nigel L.. PY - 2008/6/1. Y1 - 2008/6/1. N2 - Purpose: To investigate the relationship between intraocular pressure (IOP), retinal glutamate transport and retinal hypoxia during acute IOP elevations of varying magnitude. Methods: Female Dark Agouti rats were anaesthetized by ketamine/xylazine/ acepromazine (10/5/0.5 mg/kg i.p.). The anterior chamber was cannulated with a 30-gauge needle attached to a saline reservoir. The target IOP (20-120 mmHg, in 10 mmHg increments) was obtained by adjusting the reservoir height. After 10 mins of IOP stabilization, 2 μl of the non-endogenous glutamate transporter substrate, D-aspartate, was injected into the vitreous (final concentration 50 μm), and the elevated IOP maintained for a further 60 mins (total duration of IOP elevation was 70 mins). Glutamate transporter function ...
Time Course Changes of the Mechanical Properties of the Iris Pigment Epithelium in a Rat Chronic Ocular Hypertension Model
|i|Background|/i|. The flow field of aqueous humor correlates to the stiffness of iris pigment epithelium (IPE) which acts as a wall of posterior chamber. We focus on the variations of IPE stiffness in a rat ocular hypertension (OHT) model, so as to prepare for exploring the mechanism of duration of OHT.|i| Methods|/i|. Episcleral venous cauterization (EVC) was applied on one eye of male adult Sprague-Dawley rats to induce chronic high intraocular pressure. According to the duration of OHT (0, 1, 2, 4, and 8 weeks), rats were randomly divided into Gw0, Gw1, Gw2, Gw4, and Gw8. Atomic force microscope (AFM) analysis was applied to test IPE stiffness in three regions: iris root, mid-periphery, and pupillary-margin in each group. Histological changes of IPE were also examined in Gw4 and Gw8.|i| Results|/i|. There was an overall growing tendency of IPE stiffness in EVC eye. IPE in EVC eye was significantly stiffer than fellow eye in Gw2, Gw4, and Gw8 (in iris root, mid-periphery, and pupillary-margin, p<
Bimatoprost 0.01% in treatment-naive patients with open-angle glaucoma or ocular hypertension: An observational study in the...
TY - JOUR. T1 - Bimatoprost 0.01% in treatment-naive patients with open-angle glaucoma or ocular hypertension. T2 - An observational study in the Korean clinical setting. AU - Park, Ki Ho. AU - Simonyi, Susan. AU - kim, chanyun. AU - Sohn, Yong Ho. AU - Kook, Michael Scott. PY - 2014/12/17. Y1 - 2014/12/17. N2 - Background: This study evaluates the efficacy and tolerability (ie, occurrence and severity of hyperemia) of bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma (OAG) or ocular hypertension in the Korean clinical setting. Methods: In this multicenter, open-label, observational study, treatment-naïve patients with OAG, including patients with normal-tension glaucoma (NTG, defined as IOP ≤21 mm Hg), or ocular hypertension received bimatoprost 0.01% once daily. Hyperemia was assessed at baseline and weeks 6 and 12, graded by a masked evaluator using a photonumeric scale (0, +0.5, +1, +2, +3), and grouped as (0 to +1) and (+2 to +3). Shifts between groupings were ...
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension |...
Clinical trial for Dry Eye Disease | Eye Disease | Eye Disorders/Infections (Pediatric) | EYE DISORDER | Open Angle Glaucoma | Ocular Hypertension | Eye Disorders/Infections | Pigmentary glaucoma , Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension
Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension<...
TY - JOUR. T1 - Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension. AU - Syed, Misha F.. AU - Loucks, Emma K.R.. PY - 2011. Y1 - 2011. N2 - Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga® for treatment of glaucoma not adequately responsive to ...
Optometry Australia | Developmental Glaucoma and Ocular Hypertension | Naida Jakirlic, OD
This 1 hour course will explore the classification, pathophysiology, treatment, and management of developmental glaucoma. It will also review key points from the Ocular Hypertension Treatment Study and relate them to clinical pearls that can be used in everyday practice.
Corneal Pachymetry - Medical Clinical Policy Bulletins | Aetna
Corneal pachymetry is a non-invasive ultrasonic technique for measuring corneal thickness, and has been used primarily in the evaluation of persons with corneal diseases and in the assessment of persons at risk for glaucoma. Ultrasonic corneal pachymetry is performed by placing an ultrasonic probe on the central cornea, after the cornea has been anesthetized with a topical anesthetic. A technician can operate the pachymeter and it normally takes less than 30 seconds per eye to complete measurements.. The Ocular Hypertension Treatment Study (Kass et al, 2002; Gordon et al, 2002), a prospective randomized controlled clinical trial of glaucoma treatment in persons with elevated intra-ocular pressure (IOP) greater than or equal to 24 mm Hg, found central corneal thickness a statistically significant predictor of development of glaucoma. Corneal thickness was measured only after the study was initiated, and was not used to guide therapy. For the enrolled patients, the Ocular Hypertension Treatment ...
Intraocular pressure elevation in uveitis<...
TY - JOUR. T1 - Intraocular pressure elevation in uveitis. AU - Md. Din, Norshamsiah. AU - Mohd Isa, Hazlita. AU - Taylor, Simon R J. AU - Barton, Keith. AU - Lightman, Susan L.. PY - 2012/2. Y1 - 2012/2. N2 - Raised intraocular pressure in uveitis, either due to the disease itself or secondary to treatment with steroids, is one of the most common causes of secondary glaucoma in clinical practice. There are currently no standardized criteria for the diagnosis nor guidelines for the management of raised intraocular pressure in uveitis. Intraocular pressure elevation may be due to any combination of several mechanisms and, as a result, the prognosis differs from primary glaucomas. In addition, the management of ongoing inflammation without elevating the intraocular pressure remains a challenge. Ideally, new anti-inflammatory agents should have better anti-inflammatory properties with safer intraocular pressure profiles, while sustained release medications to lower intraocular pressure would ...
High intraocular pressure Archives - Hill Country Vision Center
by Hill Country Vision , Jan 18, 2021 , Eye Care, Eye Disease, Eye Health. Youve heard of high blood pressure or hypertension, but have you heard of high intraocular pressure or ocular hypertension? Heres everything you need to know about this eye condition, including whether or not you might be at risk. Intraocular pressure (IOP) is the ...
NCT00334750 | Open-Angle Glaucoma, Ocular Hypertension Clinical Trial | Pfizer
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada ...
Five Cases You Shouldnt Refer
Numerous randomized clinical trials have concluded that lower IOP delays or prevents progression of primary open-angle glaucoma (POAG). The Collaborative Normal Tension Glaucoma Study found slower progression in visual field defects when IOP was lowered by 30% or more.33 A faster rate of progression was noted in women, patients with migraines and those with disc hemorrhages. Notably, the untreated group was highly variable with some patients not progressing in a five-year period.33. In the Ocular Hypertension Treatment Study, researchers found topical ocular hypotensive agents were effective in delaying or preventing onset of POAG in 50% of patients with elevated IOP when IOP was decreased by 20%.34. Management. With the plethora of drug classes available, optometrists can individualize therapy based on drug allergies, systemic medications and ocular diseases. Topical drugs can be classified into three categories based on how they lower IOP: by increasing aqueous outflow via the trabecular ...
Glucocorticoids, ocular hypertension and glaucoma - UNT Health Science Center
Glucocorticoids (GCs) are commonly used anti-inflammatory and immunosuppressive therapeutic agents for a plethora of diseases and conditions. Over 1% of our population receives GC prescriptions annually. Despite the very broad and potent anti-inflammatory effects, prolonged GC therapy can cause serious side effects, including damage to the eye. Between 30-75% of individuals receiving prolonged GC therapy develop GC- induced ocular hypertension (OHT), which if unrecognized can lead to iatrogenic open-angle glaucoma and permanent vision loss. Despite recognition of this significant GC side effect for more than six decades, we still do not understand the reason for differences in susceptibility to GC-induced OHT or the mechanism(s) of action responsible for GC-OHT. We have previously shown that the alternative spliced dominant negative isoform of the glucocorticoid receptor (GRb) inhibits GC activity in cultured human TM cells. TM cells isolated from glaucoma donor eyes (GTM) have low GRb levels ...
Quark Pharmaceuticals - Quark Pharmaceuticals QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
FREMONT, Calif., Jun 28, 2010 - Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Université de Montréal. Prof. Di Polos recent study in a rat model of glaucoma shows that QPI-1007, when given in two intravitreal injections after induction of ocular hypertension (at two weeks and 10 days later), can deliver a sustained neuroprotective effect, as measured by a significant attenuation in RGC death five weeks after disease induction. Ocular neuroprotection, encompassing prevention of retinal ganglion cell (RGC) death, represents a novel approach for treating glaucoma, non-arteritic anterior ischemic optic neuropathy (NAION), and other ocular diseases.. These results support the further evaluation of QPI-1007 as a potential novel ...
Fingolimod as a neuroprotective agent for retinal ganglion cells in experimental model of ocular hypertension<...
TY - JOUR. T1 - Fingolimod as a neuroprotective agent for retinal ganglion cells in experimental model of ocular hypertension. AU - Gupta, Vivek. AU - You, Y.. AU - Klistorner, A.. AU - Graham, Stuart. PY - 2013/10. Y1 - 2013/10. M3 - Meeting abstract. VL - 19. SP - 564. EP - 564. JO - Multiple Sclerosis. JF - Multiple Sclerosis. SN - 1352-4585. IS - 11. M1 - P1189. ER - ...
Peripheral retinal ischemia following posttraumatic ocular hypertension in the setting of sickle cell trait<...
TY - JOUR. T1 - Peripheral retinal ischemia following posttraumatic ocular hypertension in the setting of sickle cell trait. AU - Cassidy, Daniel. AU - Monroig, Armando. AU - Kovach, Jaclyn. PY - 2015/3/1. Y1 - 2015/3/1. UR - http://www.scopus.com/inward/record.url?scp=84928828026&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84928828026&partnerID=8YFLogxK. U2 - 10.1001/jamaophthalmol.2014.3505. DO - 10.1001/jamaophthalmol.2014.3505. M3 - Article. C2 - 25763551. AN - SCOPUS:84928828026. VL - 133. JO - JAMA Ophthalmology. JF - JAMA Ophthalmology. SN - 2168-6165. IS - 3. M1 - e143505. ER - ...
What Causes Ocular Hypertension? | Optometrist in Mesa, AZ | Arizona Red Mountain Eye Care
What Causes Ocular Hypertension? in Mesa, AZ. Arizona Red Mountain Eye Care is your local Optometrist in Mesa serving all of your needs. Call us today at (480) 985-6211 for an appointment.
Broccoli and Saffron May Combat Ocular Diseases
Since ancient times, medicinal properties have been attributed to saffron. This spice harvested from crocus flowers contains crocin isomers, zeaxanthin, lycopene and vitamin B12, the investigators explained. In early stages of AMD, research has shown that saffron can improve visual function by reversing the damage to photoreceptors and bipolar cells caused by oxidative stress. In another investigation considered in the study, daily saffron intake improved retinal changes in patients with both dry and wet AMD.. Considering glaucoma, the researchers analyzed saffron in a mouse model of chronic ocular hypertension and found that saffron extract resulted in a reduction in both the number and signs of microglial cell activation as well as a down-regulation of the purinergic receptor P2RY12a, a marker of inflammation-related non-activated microglia. In addition, saffron also prevented the retinal ganglion cells death that occurred in chronic hypertensive eyes, suggesting the neuroprotective effect of ...
UNTHSC Scholarly Repository - Summer Research Internship Program: EFFECT OF BAMBI EXPRESSION ON THE ECM OF TRABECULAR MESHWORK...
Purpose: Elevated intraocular pressure (IOP) is one of the main risk factors in the development of glaucoma. TGFβ2 is well known to be involved in regulating both the extracellular matrix in the trabecular meshwork (TM) as well as ocular hypertension. BAMBI (BMP and activin membrane-bound inhibitor) has been shown to be a negative regulator of TGF-β2. However, the role of BAMBI in regulating IOP is unknown. We investigated whether knockdown of BAMBI results in ocular hypertension in mice changes to the ECM in the TM due to uninhibited TGFβ2 signaling. Methods: B6;129S1-Bambitm1Jian/J mice were injected intravitreally with 2.5x107 pfu of either Ad5.TGFβ2 (n=10), Ad5.Cre (n=9), or Ad5.TGFβ2 + Ad5.Cre (n=10), in one eye of each animal. The contralateral uninjected eyes were used as negative controls. IOP was measured using a TonoLab rebound tonometer. BAMBI and Fibronectin expression was assessed in the TM by immunohistochemistry on cross-sections of eyes from Bambitm1Jian/J floxed mice and
Primary Open-angle Glaucoma and Ocular Hypertension - Graybug Vision
Factors contributing to the lack of compliance include forgetfulness, difficulty with drop self-administration, and difficulty with medication schedule. Lack of adherence has been shown to correlate with the progression of vision loss. A key unmet medical need is the availability of new technology to address low medication adherence.. Graybug is developing a drug-encapsulated microparticle formulation to provide continuous IOP-lowering that is administered by the treating physician every 3 to 6 months using a subconjunctival injection. The goal is to enhance the overall consistency of medical care by placing medication compliance into the hands of the treating physicians rather than the patient.. Graybug has developed a library of over 100 new molecular entities (NME) based upon pro-drugs of approved IOP-lowering agents, rho-kinase receptor inhibitors (ROCK), and other novel IOP-lowering agents. The flexible and unique Graybug platform allows three different approaches (Figure 2) where an ...
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension -...
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution
Elevated intraocular pressure; glaucoma of the eye; treatment
Glaucoma of the eye, which is often interpreted as elevated intraocular pressure, is a disease that is one of the leading causes of blindness in the world. This is a condition in which normal flow of aqueous water through the eye is disrupted, and then eye swells. This is what causes high levels of intraocular pressure within the eye, damaging the optic nerve at the same time and leads to the collapse of the visual field, and finally to loss of vision ...
Can you tell me the relationship between inter ocular pressure and sugar level - Tips and Tricks From Doctors
Helpful, trusted answers from doctors: Dr. Chang on can you tell me the relationship between inter ocular pressure and sugar level: Blood sugar can cause retinopathy (damage to the retina) and increased near sightedness but does not affect ocular pressure.
Molecular and functional alterations in rat retinas during different periods of elevated intraocular pressure (IOP):...
Molecular and functional alterations in rat retinas during different periods of elevated intraocular pressure (IOP): experimental glaucoma Conference Poster 2008 Congress communication ...
Variability of the risk factors measurements and 5-year glaucoma risk estimation. | Abstract
The risk factors of the development of primary open angle glaucoma (POAG) in patients with ocular hypertension (OHT) were identified according to the ..
Article Metrics] Objective assessment of compliance and persistence among patients trea | PPA
Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review Gregory Reardon1, Sameer Kotak2, Gail F Schwartz3 1Informagenics, LLC, Worthington, OH, USA; The Ohio State University College of Pharmacy, Columbus, OH, USA; 2Pfizer Inc, New York, NY, USA; 3Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA Purpose: This study summarizes findings from objective assessments of compliance (or adherence) and persistence with ocular hypotensive agents in patients with glaucoma and ocular hypertension. Design: Systematic literature review. Methods: A PubMed and reference list search was conducted across publication years 1970–2010, using these terms and variants: "compliance," the equivalent term "adherence," and "persistence" in patients with these conditions and therapies. Summaries of selected studies were stratified by measurement
High Intraocular Pressure - Eye Care - MedHelp
My intraocular pressure is a little higher than average and my doctor- he is specialist of glaucoma- advise me to apply eye lotion to prevent from glaucoma, but recently Ive have some doubts about his...
DMOZ - Health: Pharmacy: Drugs and Medications: T: Travoprost
Travaprost is an opthalmic solution used in the treatment of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications.
Bimatoprost 0.01% approved for reduction of IOP | Ophthalmology Times
Irvine, CA? Allergan, Inc. recently announced the approval by the FDA of a 0.01% bimatoprost ophthalmic solution 0.01% (LUMIGANLumigan) as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Getting control of my Inta Ocular Pressure - Doctors insight on HealthcareMagic
Question - Getting control of my Inta Ocular Pressure. Ask a Doctor about diagnosis, treatment and medication for Cracker injury, Ask an Ophthalmologist
Glaucoma risk factors: When to initiate therapy | Ophthalmology Times
Initiating medical therapy for patients with ocular hypertension or with suspected glaucoma should include careful history taking and examination, testing, and discussion with patients, said Paul Harasymowycz, MD.
Publications of Faculty of Medicine: Intraocular Pressure-reducing Effect of Latanoprost Versus Timolol in Patients with Open...
Paper: Intraocular Pressure-reducing Effect of
Latanoprost Versus Timolol in Patients
with Open angle glaucoma and Ocular
Hypertension , Author: Waheed M. Orouk MD
Sherif N. Abdel Salam MD , Year: , Faculty of Medicine, Benha University
brimonidine ophthalmic - WellSpan Health Library
Brimonidine reduces the amount of fluid in the eye, which decreases pressure inside the eye. Brimonidine ophthalmic (for the eyes) is used to treat open-angle glaucoma or ocular hypertension (high pressure inside the eye). Brimonidine ophthalmic may also be used for purposes not listed in this medication guide.
World Glaucoma Week - Eye Opticians
World Glaucoma Week march 12th -18th 2017 Glaucoma is a blinding condition that affects 2% of the population over the age of 40. This rises to 10% in the over 75 in white Europeans and glaucoma also account to approximately 10% of the blind register.. The risk increases if there is a family history of glaucoma, you have got high pressure or ocular hypertension and if you are short sighted of Afro Caribbean origin. Some studies have cited high blood pressure and diabetes as potential risk factors. The hallmark of glaucoma is damage to the main nerve inside the eye, the Optic Nerve. The earlier the detection the better the prognosis. ...
V Glaucoma Implementing NICE guidance 2009 NICE clinical guideline ppt download
Background Chronic open angle glaucoma (COAG) is a common and potentially blinding condition, and is usually asymptomatic until advanced Ocular hypertension (OHT) is a major risk factor for developing COAG Approximately 10% of UK blindness registrations are attributed to glaucoma By implementing this guideline more people will be prevented from going blind
Brimonidine Eye Drops
Glaucoma - Mackie Opticians
Attending regular optician appointments will help to ensure any signs of glaucoma can be detected early and allow treatment to begin.You are entitled to a free NHS eye test if you are over 40 years old and have a first-degree relative (mother, father, sister or brother) with glaucoma. Risk factors include Myopia (Short-Sight), Family History, Afro-Caribean and Chinese ethnicity, Diabetes, High Hyperopia (Long Sight). Instrumentation used includes OCT (see 3D scan (link)), Visual Fields (peripheral vision), Tonometry (measure of the pressure of your eye), Pachymetry (thickness of your cornea), and Volk Bio-microscopy (retina optic nerve head).. New SIGN and NICE guidelines have been introduced to improve detection and reduce unnecessary referrals using the Disc Damage Likelihood Scale and IOP over 25 for Ocular Hypertension.. ...